- Ongoing, recruitingTherapeutic exploratory (Phase II)
A randomised controlled trial of a moisturiser for treatment of dry skin in atopic dermatitis: effect on the skin barrier in adults with a history of eczema
This study is looking at how well different moisturisers work to improve dry skin in adults who have a history of eczema. Researchers want to see if a new moisturiser can strengthen the skin's protective barrier compared to other treatments or no treatment at all.
For: Atopic dermatitisGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
An open-label, non-randomized, biopsy-based mechanistic study on pharmacokinetics, pharmacodynamics, safety and tolerability of ianalumab in patients with Sjögren's syndrome
This study is looking at a new medicine called ianalumab for Sjögren's syndrome. We want to see how it affects cells in the salivary glands, how safe it is, and how the body uses it. This is an early-stage study.
For: Sjögren's syndromeFrance - Ongoing, recruitingPhase II and Phase III (Integrated)
A randomized, open label, multicenter phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic, refractory colorectal cancer patients (TROPHIT1)
This study is looking at a new treatment called sacituzumab govitecan for bowel cancer that has spread and isn't responding to other treatments. It compares this new drug to standard treatments to see which works best at stopping the cancer from growing.
For: Metastatic Colorectal cancer (mCRC)Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 positive Colorectal Cancer (KEYFORM-007)
This study looks at a new drug combination, MK-4280A, for bowel cancer that has spread and has been treated before. It compares this new treatment to standard care to see if it helps people live longer and improves their quality of life.
For: Colorectal CancerItaly · Norway · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable /Metastatic Solid Tumors Who are Refractory to Available Standard Therapies
This study is testing a new medicine called SKB264 for people with advanced solid tumours that haven't responded to other treatments. It's a first step to see how safe and effective SKB264 is, and to understand its effects on the body.
For: Metastatic or locally advanced unresectable solid tumors progressing after available standard therapiesSpain · Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A phase III, international, multiCenter, randomized, paraLlel-group, Endoscopist-blinded non-inferiority study of the efficAcy, safety and patient acceptance of mannitol veRsus Plenvu® in boWel prepAration for elective colonoscopY. CLEARWAY
This study, called CLEARWAY, is comparing two different bowel preparations, Mannitol and Plenvu, used before a colonoscopy. It aims to see if Mannitol is as good as Plenvu at cleaning the bowel, while also checking for any differences in safety and how easy they are for patients to use.
For: Subjects scheduled for elective colonoscopy performed according to ESGE (European Society of Gastrointestinal Endoscopy) guidelines.Belgium · Spain · Sweden - AuthorisedTherapeutic use (Phase IV)
Long-term muscle synthetic effects of intradialytic parenteral nutrition in chronic hemodialysis patients
This study looks at how a special nutrient feed given during dialysis (IDPN) affects muscle strength in people with chronic kidney disease. It compares muscle building with and without this extra feed to see if it makes a difference over time.
For: muscle protein turnover hemodialysisNetherlands - AuthorisedTherapeutic exploratory (Phase II)
J2R-MC-YAAD: A Phase 2, Double-blind, Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant Disease
This study is looking into a new medicine called LY3537021 (also known as Lagipra) to help prevent sickness and vomiting caused by chemotherapy. It compares the new medicine to a dummy pill (placebo) and other common anti-sickness treatments in adults having cancer treatment.
For: Drug-Related Side Effects and Adverse Reactions · Nausea · NeoplasmsRomania · Spain · France